For cases that displayed GOM at RB1 and NNAT/BLCAP, 85% and 80%, respectively were classified as stage 4 tumours, although we also see stage 4 tumour cases (41%) in the “No change” group at RB1. Loss of methylation at MAGEL2 was predominantly associated with stage 4 tumours (87% of cases in LOM group and 63% of cases in the Intermediate LOM group) (Fig. 3B). This evidence concerns the gene MAGEL2 and neoplasm.